PRU Achieves a Global Milestone: Receives ANVISA Certificate of Good Practices in Bioavailability/Bioequivalence
The Pharmaceutical Research Unit is proud to announce a remarkable achievement that marks a new chapter in our journey of excellence.
We have officially received the Certificate of Good Practices in Bioavailability/Bioequivalence from ANVISA, the Brazilian Health Regulatory Agency, one of the world’s most respected and most stringent regulatory authorities.
This certification is not only an honor but a rare accomplishment, as ANVISA approvals are known for their rigorous standards and demanding requirements. It is a powerful recognition of PRU’s unwavering commitment to global compliance, robust quality systems, and scientific excellence in bioequivalence and bioavailability research.
Earning this certification strengthens PRU’s standing as a trusted and strategic partner for pharmaceutical companies worldwide. It validates our ability to support regulatory submissions and accelerate access to international markets, reinforcing our role as a center of excellence in clinical research.
As we celebrate this historic milestone, we renews its commitment to continuous improvement and innovation, ensuring that every study we conduct not only meets but exceeds global expectations, while contributing to strengthening international research excellence.
